

# **EXHIBIT 31**

IN THE UNITED STATES COURT  
NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION

~~~~~  
IN RE: NATIONAL PRESCRIPTION MDL NO. 2804  
OPIATE LITIGATION

Case no. 7-mdl-284

Judge Dan Aaron Polster

This document relates to:

The County of Summit, Ohio, et al., v. Purdue  
Pharma L.P., et al.,

Case No. 1:18-OP-45090 (N.D. Ohio)

Case No. 17-OP-45005

Case No. 18-OP-45090

~~~~~  
Videotaped deposition of  
CHAD GARNER  
November 14, 2018  
8:35 a.m.

Taken at:  
Sheraton Columbus Capital Square  
75 East State Street  
Columbus, Ohio  
Wendy L. Klauss, RPR

1           A.       I'm sorry. Which side are we  
2 talking about?

3           Q.       This is prescriber side.

4           A.       Prescriber side. Again, there are  
5 a number of different ways that we do this, you  
6 know, looking for overprescribing sometimes of  
7 specific drugs or combinations of drugs.

8                   It could also be, you know,  
9 violations by a patient, different things that  
10 would indicate overuse or misuse. Also, you  
11 know, dispensing patterns, dispensing  
12 combinations of drugs that would be ill  
13 advised. A pharmacy that maybe should have  
14 seen something and stopped it that did not,  
15 would be another. There are many, many  
16 different things we could look at.

17           Q.       Okay. So on the prescriber side,  
18 you've identified some analyses that you and  
19 your staff are able to do on the database that  
20 indicate potential crime, such as the  
21 overprescription of drugs, the prescription of  
22 dangerous combinations of drugs, et cetera,  
23 right?

24           A.       Correct.

25           Q.       How long has the OARRS database

1       been able to do this type of analysis?

2               A.       Again, the database has always been  
3       able to do it. It was a matter of staff --  
4       having the capacity within the staff of doing  
5       it.

6               Q.       And at what point did OARRS have  
7       the staff capacity to run the types of reports  
8       we just discussed that are indicative of  
9       potential crime?

10              A.       We've -- we've done, to a certain  
11       extent, all along. It's just it has grown.  
12       It's not, you know -- it started small and it  
13       has grown over time.

14              Q.       Does OARRS run or perform analyses  
15       of the wholesale side of OARRS for the purpose  
16       of identifying potential crime?

17              A.       Yes, at times.

18              Q.       And what types of analyses are  
19       those that are run on the wholesale side?

20              A.       It could be purchases, especially  
21       by prescribers, of more drugs than they are  
22       permitted to dispense from their office in a  
23       given period of time; purchases that would not  
24       make sense for a particular type of prescriber;  
25       purchases that are not later reported as being

1 dispensed. It would be a few.

2 Q. On purchases by prescribers of more  
3 drugs than are permitted -- they are permitted  
4 to dispense, how do you, at OARRS, know how  
5 much a prescriber is permitted to dispense?

6 A. It is in the statute.

7 Q. It is an Ohio statute?

8 A. Yes.

9 Q. How frequently have you run or  
10 performed the analysis on purchases by a  
11 prescribers of more drugs than they are  
12 permitted to dispense?

13 A. It's on an ad hoc basis. I would  
14 say a couple times a year.

15 Q. And how many times have you run  
16 analyses of purchasers -- or purchases that do  
17 not make sense for the type of prescriber?

18 A. A handful of times.

19 Q. You mentioned that you also run  
20 analyses on the prescription side of the OARRS  
21 database when assisting with investigations; do  
22 you recall that?

23 A. Yes.

24 Q. We talked earlier about some  
25 reports that are run in the context of

1 patient is taking, combinations of drugs, you  
2 know, historical patterns.

3 Q. And doctor shopping can be  
4 recognized through the use of the OARRS  
5 database, correct?

6 A. Yes.

7 Q. Can the amount of drugs that a  
8 patient is using be revealed through the OARRS  
9 database?

10 A. Yes.

11 Q. And can the OARRS database reveal  
12 combinations of drugs taken by a particular  
13 patient?

14 A. Yes.

15 Q. Are you responsible for writing the  
16 grant proposals?

17 A. No.

18 Q. Who does that?

19 A. Cameron McNamee.

20 Q. Do you have any input on the grants  
21 for which you apply?

22 A. Yes.

23 Q. What input do you have into the  
24 selection of grants that you will apply for?

25 A. Typically, I typically have a

1 the gender of the patient reported?

2 A. Yes.

3 Q. And the date of birth and gender of  
4 the patient, the requirement that those be  
5 reported, that's always been the case?

6 A. Yes.

7 Q. What about the medical history of a  
8 patient, is that reported through OARRS?

9 A. No.

10 Q. Does the system capture overlapping  
11 prescriptions from multiple prescribers?

12 A. So assuming each prescription is a  
13 controlled substance, each prescription would  
14 be reported. So if we looked for it, we would  
15 be able to tell whether two prescriptions  
16 overlapped.

17 Q. And that's the same data that you  
18 would use to identify, for example, a doctor  
19 shopper?

20 A. Correct.

21 Q. We talked about data that  
22 identifies the transaction history of a  
23 particular OARRS accountholder.

24 How long does this information that  
25 is reported by prescribers and dispensers, how

1 bottle came from distributor A and this one  
2 from distributor B.

3 Q. Can OARRS collate data, daily  
4 dispensing information for a particular  
5 terminal distributor over time to detect  
6 spikes?

7 A. Yes.

8 Q. Can OARRS collate daily dispensing  
9 information over time to determine who  
10 prescribed an opioid?

11 A. Yes.

12 Q. Can OARRS collate daily dispensing  
13 information to determine to whom a prescription  
14 was dispensed on a specific day where there was  
15 a spike?

16 A. Yes.

17 Q. When we were talking about reports,  
18 and they are made by prescribers and -- let me  
19 back up.

20 Individuals who have access to  
21 OARRS, and we talked about the fact that  
22 pharmacists have accounts but a pharmacy itself  
23 does not, right?

24 A. Correct.

25 Q. Can a pharmacy, like a corporate